I. Hemostasis and Desmopressin.- Regulation of Haemostasis: The Role of Arginine Vasopressin.- Von Willebrand Factor and P-Selectin Targeting to and Release from Endothelial Cell-Specific Storage Granules.- Factor VIII in Monkeys, Effect of DDAVP Analogues.- Possible Involvement of Serotonin in the Haemostatic Action of DDAVP in Patients with Uraemia.- Molecular Mechanisms of Cellular Responses to DDAVP.- II. Phemacology and Pharmacodynamics of Desmopressin.- Some Pharmacological Properties of Desmopressin.- Pharmacokinetics of Desmopressin.- Fall-Off of Factor VIII Elicited by Desmopressin Administration in Hemophiliacs and von Willebrand’s Disease Patients.- Toxicity of Desmopressin and Related Peptides.- The Hemodynamic and Coagulant Effects of dDAVP are Specific Extrarenal V2-Receptor Responses.- The Vasopressin Antagonist SK&F 105494 Inhibits Desmopressin-Stimulated Clotting Factor Release in vivo.- Non-Responsivess of t-PA, u-PA, and vWF to DDAVP.- III. Desmopressin in Renal Disease.- Control of Bleeding in Uremic Patients.- Hemostatic Effectiveness of Desmopressin in the Bleeding Disorders of Uremia.- Renal Function and Thromboembolism in High Dose Desmopressin Treatment.- IV. Desmopressin and Platelets.- DDAVP Corrects the Platelet Dysfunction Produced by Cardiopulmonary By-Pass, Hemodialysis and Prolonged Storage: Re-Expresion of Glycoprotein Ib on the Platelet Membrane.- Desmopressin in the Treatment of Congenital and Acquired Defects of Platelet Functions.- The Effectiveness of Desmopressin in Patients with Disorders of Primary Haemostasis.- Clinical Efficacy of Desmopressin and Consistency of Responses to Separate Infusion in Patients with Prolonged Bleeding Time Due to Congenital Platelet Defect.- V. Desmopressin and Surgery.- Desmopressin, von WillebrandFactor and Surgery.- Desmopressin in Cardiac Surgery with Extra-Corporeal Circulation.- Desmopressin Corrects the Hemostatic Disorder Induced by Dextran and Regional Anesthesia in Total Hip Replacement.- VI. Desmopressin and Blood Donation.- Effects of Desmopressin on Normal Donors in Plasma Exchange Donations.- The Use of DDAVP in Blood Donors to Increase the Yield of Factor VIII in the Preparation of Factor VIII Concentrates.- VII Clinical Applications of Desmopressin in Hemophilia and von Willebrand’s Disease.- Epidemiology of Mild and Moderate Hemophilia A and von Willebrand’s Disease.- An Overview of Gene Alterations in Mild Hemophilia and von Willebrand Disease.- DDAVP — Clinical Use and Therapeutic Limitations in Patients with Congential Bleeding Disorders: The Auckland Experience.- Multicenter Evaluation of a New Concentrated Desmopressin Preparation (Emosint) Administered Intravenously or Subcutaneously: Analysis of Biological Responses and Side-Effects in 49 Patients with Hemophilia A and von Willebrand’s Disease.- Management of Spontaneous Bleeding and Prevention of Bleeding after Dental Extractions and Other Surgical Procedures in Mild Hemophilia A and von Willebrand’s Disease: Ten Years of Experience at the Vicenza Hemophilia and Thrombosis Center.- Multicenter Italian Study on Subcutaneous Concentrated Desmopressin (Emosint) for the In-Hospital and Home Treatment of Patients with von Willebrand Disease and Mild or Moderate Hemophilia A: Outline of the Project.- Desmopressin: An Overview of Present and Future Indications with a Review of Investigations Performed at the University of Manitoba, 1981–1989.- VIII. Clinical Applications of Desmopressin in Hemophilia and von Willebrand’s Disease (Second Part).- Desmopressin in Acquired Hemophilia.-Intravenous and Subcutaneous Desmopressin: Clinical Results.- Intranasal Application of DDAVP: Biological Function, Pharmacokinetics and Reproducibility.- Use of Highly Concentrated Intranasal Spray Formulation of Desmopressin in Persons with Congenital Bleeding Disorders.- Nasal Spray Desmopressin: Laboratory and Clinical Implications.- IX. Side-Effects and Adverse Reactions of Desmopressin.- DDAVP and Tachyphylaxis in Healthy Subjects.- Biological Responses to Repeated Doses of Desmopressin (DDAVP) in Patients with Hemophilia and von Willebrand’s Disease.- Myocardial Infarction and Stroke: Is the Risk Increased by Desmopressin?.- X. Recapitulation.- DDAVP in the Management of Congential and Acquired Bleeding Disorders: Solved and Unsolved Issues.
